Summary
IDEXX Laboratories, Inc. reported strong third-quarter results, demonstrating robust revenue growth driven by its core Companion Animal Group (CAG) segment. Total revenue increased by 6.6% year-over-year to $975.5 million, with organic revenue growing by 6.1%, highlighting the company's ability to drive growth through a combination of price realization and volume increases across its diagnostic consumables and services. The company maintained healthy profitability, with gross profit margin improving to 61.1% and operating income rising by 10.4% to $303.9 million. This financial performance was supported by effective cost management and favorable business mix, despite ongoing inflationary pressures. IDEXX also continues to execute its capital allocation strategy, with significant share repurchases and investments in growth, while maintaining a strong liquidity position and compliance with financial covenants.
Financial Highlights
53 data points| Revenue | $975.54M |
| Cost of Revenue | $379.50M |
| Gross Profit | $596.04M |
| R&D Expenses | $53.98M |
| Operating Expenses | $292.15M |
| Operating Income | $303.89M |
| Net Income | $232.84M |
| EPS (Basic) | $2.83 |
| EPS (Diluted) | $2.80 |
| Shares Outstanding (Basic) | 82.30M |
| Shares Outstanding (Diluted) | 83.06M |
Key Highlights
- 1Total revenue for the third quarter increased by 6.6% to $975.5 million, driven by a 6.1% organic revenue growth.
- 2The Companion Animal Group (CAG) segment continues to be the primary growth driver, with revenue up 6.5% to $892.0 million, fueled by recurring diagnostics and software services.
- 3Gross profit margin improved to 61.1% from 59.9% in the prior year, reflecting favorable business mix, pricing power, and cost management.
- 4Operating income saw a significant increase of 10.4% to $303.9 million.
- 5The company maintained a strong liquidity position, with cash and cash equivalents of $308.6 million and an available borrowing capacity of $998.2 million under its credit facility.
- 6Significant share repurchases were executed, with $225.2 million spent in the third quarter and $610.7 million year-to-date, demonstrating a commitment to returning capital to shareholders.
- 7The company announced an increase in its accrual for an ongoing litigation matter to $89.0 million, which impacted general and administrative expenses but did not derail overall operational performance.